Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
CLLS · against 104 other Healthcare companies of similar size
Ranked #46 of 105 · scores higher than 38% of peers
Bars: peers in each 10-point band of the valuation score32 peers with a valuation score of 30–39, including CLLS · Click a bar to see the companies
Mainly because of its earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | CLLS | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 89 reported | -58.7% | -13.3% | 25% | 30% | |
| EBITDA yieldHigher is better · 113 reported | 589.8% | -2.5% | 96% | 50% | |
| Free cash flow yieldHigher is better · 78 reported | -41.0% | -15.8% | 27% | 20% | |
| Book yieldHigher is better · 94 reported | 51.8% | 75.6% | 35% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 834M HKD (≈$107M) | 99 | 57 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 1 | 592M ILS (≈$160M) | 99 | 84 | |
| 46 | 205M USD | 33 | 36 | |
| 46 | 111M USD | 33 | ||
| 46 | 186M USD | 33 | 43 | |
| 46 | 100M USD | 33 | 37 | |
| 46 | 110M USD | 33 | 38 | |
| 46 | 213M USD | 33 | ||
| 46 | 109M USD | 33 | 47 | |
| 46 | 216M USD | 33 | 44 | |
| 46 | 126M USD | 33 | 32 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score